p21Waf1/Cip1 as a therapeutic target in breast and other cancers

This publication has 42 references indexed in Scilit:

• ErbB2 overexpression in human breast carcinoma is correlated with p21^Cip1 up‐regulation and tyrosine‐15 hyperphosphorylation of p34^Cdc2
  Cancer, 2003
• The Cyclin-dependent Kinase Inhibitor p21CIP/WAF Is a Positive Regulator of Insulin-like Growth Factor I-induced Cell Proliferation in MCF-7 Human Breast Cancer Cells
  Published by Elsevier ,2003
• Ets-1 Protects Vascular Smooth Muscle Cells from Undergoing Apoptosis by Activating p21WAF1/Cip1
  Published by Elsevier ,2003
• Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells
  Oncogene, 2003
• Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage
  Nature, 2002
• Novel polymorphism in p21waf1/cip1 cyclin dependent kinase inhibitor gene: association with human esophageal cancer
  Oncogene, 2000
• Disruption of p53 in human cancer cells alters the responses to therapeutic agents
  Journal of Clinical Investigation, 1999
• Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard
  Oncogene, 1997
• p21 is a universal inhibitor of cyclin kinases
  Nature, 1993
• WAF1, a potential mediator of p53 tumor suppression
  Cell, 1993